H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating and $30.00 price target on First Tracks Biotherapeutics (NASDAQ: TRAX).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE